IPA (ImmunoPrecise Antibodies) LT-Debt-to-Total-Asset : 0.25 (As of Jan. 2025)

View and export this data going back to 2011. Start your Free Trial

What is ImmunoPrecise Antibodies LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. ImmunoPrecise Antibodies's long-term debt to total assests ratio for the quarter that ended in Jan. 2025 was 0.25.

ImmunoPrecise Antibodies's long-term debt to total assets ratio increased from Jan. 2024 (0.16) to Jan. 2025 (0.25). It may suggest that ImmunoPrecise Antibodies is progressively becoming more dependent on debt to grow their business.

ImmunoPrecise Antibodies LT-Debt-to-Total-Asset Historical Data

The historical data trend for ImmunoPrecise Antibodies's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmunoPrecise Antibodies LT-Debt-to-Total-Asset Chart

ImmunoPrecise Antibodies Annual Data

Trend

Dec14

Dec15

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

Apr24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.06

0.04

0.01

0.08

0.20

ImmunoPrecise Antibodies Quarterly Data
	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.16	0.20	0.20	0.20	0.25

ImmunoPrecise Antibodies LT-Debt-to-Total-Asset Calculation

ImmunoPrecise Antibodies's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Apr. 2024 is calculated as

LT Debt to Total Assets (A: Apr. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Apr. 2024 )	/	Total Assets (A: Apr. 2024 )
	=	8.862	/	43.87
	=	0.20

ImmunoPrecise Antibodies's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jan. 2025 is calculated as

LT Debt to Total Assets (Q: Jan. 2025 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jan. 2025 )	/	Total Assets (Q: Jan. 2025 )
	=	7.811	/	31.645
	=	0.25

ImmunoPrecise Antibodies (NAS:IPA) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

ImmunoPrecise Antibodies LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of ImmunoPrecise Antibodies's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

ImmunoPrecise Antibodies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmunoPrecise Antibodies Ltd (NAS:IPA) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

TQB:Germany TQB:Germany

Address

3204 - 4464 Markham Street, Victoria, BC, CAN, V8Z 7X8

Website

https://www.ipatherapeutics.com

ImmunoPrecise Antibodies Ltd is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series proprietary and patented technologies. The company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges.